No profile data available.
Connect Biopharma Holdings Limited (CNTB) is a healthcare company in the additional breathing treatment drugs industry, based in San Diego, United States, with about 64 full-time employees.
It reported revenue of $64,000 for fiscal year 2025, down 99.8% from fiscal year 2024, and net income of -$55.48 million. Its market capitalization was $54.79 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Connect Biopharma Holdings reported $64,000 in revenue for fiscal year 2025, down 99.8% from $26.03 million in fiscal year 2024.
$54.79 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional breathing treatment drugs) include Lyra Therapeutics, Inc. (LYRA).